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Abstract
Experimental and clinical studies have shown that aldosterone/mineralocorticoid receptor (MR) activation has deleterious
effects in the cardiovascular system; however, the signalling pathways involved in the pathophysiological effects of
aldosterone/MR in vivo are not fully understood. Several in vitro studies suggest that Epidermal Growth Factor Receptor
(EGFR) plays a role in the cardiovascular effects of aldosterone. This hypothesis remains to be demonstrated in vivo.T o
investigate this question, we analyzed the molecular and functional consequences of aldosterone exposure in a transgenic
mouse model with constitutive cardiomyocyte-specific overexpression of a mutant EGFR acting as a dominant negative
protein (DN-EGFR). As previously reported, Angiotensin II-mediated cardiac remodelling was prevented in DN-EGFR mice.
However, when chronic MR activation was induced by aldosterone-salt-uninephrectomy, cardiac hypertrophy was similar
between control littermates and DN-EGFR. In the same way, mRNA expression of markers of cardiac remodelling such as
ANF, BNF or b-Myosin Heavy Chain as well as Collagen 1a and 3a was similarly induced in DN-EGFR mice and their CT
littermates. Our findings confirm the role of EGFR in AngII mediated cardiac hypertrophy, and highlight that EGFR is not
involved in vivo in the damaging effects of aldosterone on cardiac function and remodelling.
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Introduction
Mineralocorticoid excess and MR implication in cardiac
diseases have extensively been studied the last decade, and the
involvement of MR activation in the development of several heart
diseases has been demonstrated through the use of specific MR
antagonists (spironolactone, eplerenone) in clinical and experi-
mental studies. The RALES, EPHESUS and EMPHASIS studies
demonstrated that MR blockade reduces remarkably mortality
in patients with heart failure [1] [2] [3]. Pharmacological MR
antagonism also prevents cardiac damages in several animal
models such as spontaneously hypertensive rats, uninephrecto-
mized rats treated with aldosterone-salt, heart failure after
myocardial infarction or aortic banding [4]. Although progresses
have been accomplished, the mechanisms underlying aldosterone-
induced contributions to myocardial remodelling and the
progression of cardiovascular diseases are still under investigation.
The activation of Epidermal Growth Factor Receptor (EGFR)
has been proposed to play a role in the cardiovascular effects of
aldosterone, particularly in the crosstalk between aldosterone and
Angiotensin II (AngII) [5]. Several studies support a relation
between aldosterone and EGFR. Ex vivo, aldosterone increased
renal, endothelial and vascular smooth muscle cells EGFR
expression and/or activation. Furthermore, in these cell types
downstream EGFR signaling cascades are induced upon addition
of aldosterone or prevented by MR blockade [6]. In vivo cardiac
and aortic EGFR expressions are increased in adrenalectomized
rats treated with aldosterone [7]. We recently demonstrated that
EGFR mediates the vascular dysfunction but not the remodelling
in uninephrectomized mice treated with aldosterone/salt [8].
However, the role of EFGR activation in the pathogenic effects of
aldosterone in the heart in vivo remains to be demonstrated.
We hypothesized that EGFR activation might contribute to the
damaging effects of aldosterone in the heart in vivo. To investigate this
question, we analyzed the molecular and functional consequences of
aldosterone exposure in a transgenic mouse model with constitutive,
cardiomyocyte-specific overexpression of a truncated EGFR protein
acting as a dominant negative (DN-EGFR). This model has been
successfully used to block cardiac EGFR transactivation by AngII [9].
This mouse model was challenged with either AngII or
aldosterone (associated to uninephrectomy and high salt diet).
The results obtained in this study confirm the role of EGFR in
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30156AngII mediated cardiac hypertrophy, and highlight that EGFR is
not involved in vivo in the damaging effects of aldosterone/salt on
cardiac function and remodelling.
Methods
Mice
Mice expressing a dominant negative isoform of EGFR (DN-
EGFR) in the cardiomyocytes only were generated on a FVB
background, using the a-myosin heavy chain promoter to achieve
cardiac-specific expression (see [9] for further details).
Experiments were conducted in accordance with the standard
ethical guidelines (National Institutes of Health’s ‘‘Guide for the
care and use of Laboratory animals’’, and the European
Communities Council European Communities Directive 86/609
EEC. Approval ID: Ce5/2009/034, delivered the 11/12/2009.
All experiments involving mice were approved by the Ile de
France Regional Ethics Committee for Animal Experiments.
Angiotensin II treatment
Adult male DN-EGFR mice and wild-type littermates used as
controls (CT) were treated with AngII (200 ng/kg/min) or vehicle
(0.9% sodium chloride) infused during 2 weeks using osmotic mini-
pumps (model 2002, Alzet, Charles River Laboratories, Inc.).
Nephrectomy aldosterone-salt treatment (NAS)
Adult male DN-EGFR mice and their wild-type littermates
(CT) were used. To generate the Aldosterone-salt hypertensive
mice, mice underwent left uninephrectomy and were implanted
with osmotic minipumps filled with aldosterone (60 mg/kg/d) or
vehicle (EtOh10%), (model 2006, Alzet, Charles River Laborato-
ries, Inc.). After one day recovery, animals treated with
aldosterone were given 1% NaCl in the drinking water for 2 or
4 weeks.
Blood pressure, echocardiographic analysis
Systolic BP (SBP) was measured by tail cuff plethysmography in
trained conscious mice using a BP2000 Visitech model (Bioseb,
Chaville, France). Echocardiography was performed on lightly
anesthetized mice (isofluorane, Abott, in oxygen), as previously
described [10].
Organ weights
At sacrifice, heart and kidneys was removed and weighed. Tibia
length was measured. Organs were snap frozen in liquid nitrogen
and stored at 280uC for molecular analysis.
Fibrosis
Cardiac cryostat sections (7 mm) were stained with the collagen
specific Sirius red stain (0.5% in saturated picric acid). Sections
were double-blinded observed in microscope and quantified.
Quantitative polymerase chain reaction in real time (real
time Q-PCR)
Frozen hearts were crushed in Trizol (Invitrogen, Cergy
Pontoise, France) in tubes specific for lysis (Lysing D matrix,
QBiogene, Illkirch, France). Total RNAs were extracted using
phenol chloroform and treated with DNase I (Ambion, Applied
Biosystems, Courtaboeuf, France). Reverse-transcription was
performed using the reverse transcriptase Superscript II (200 U/
ml, Invitrogen, Cergy Pontoise, France) as previously described
[10].
Real time Q-PCR was carried out on an iCycler (Biorad
Laboratories, Marnes La Coquette, France) using gene-specific
primers to quantify the relative abundance of each gene with
SYBR Green I as the fluorescent molecule as described [10]. The
primers used are listed in Table 1. The ubiquitin (UBC) gene was
used as the reference gene for normalization. The relative
expression of the target genes was calculated with the 2
(2DDCt)
method as described [10].
Statistics
Values are means 6 SEM. Differences between groups were
assessed with ANOVA-2 or KRUSKALL-WALLIS tests (Statview
software). Values of p#0.05 were considered significant.
Results
DN-EGFR mice and AngII treatment
DN-EGFR mice constitutively express a cardiomyocyte-specific
dominant-negative form of EGFR. As previously reported [9] and
confirmed in the present study (Fig. 1; Table 1), the constitutive
DN-EGFR expression did not modify cardiac function, morphol-
ogy or size. In CT mice, two weeks of AngII perfusion induced a
cardiac hypertrophy as revealed by the increase (+13%, p,0.05) of
heart weight/tibia length (HW/TL) ratio, but failed to induce the
same phenotype in DN-EGFR mice (Fig. 1a). In the same way,
cardiac gene expression of Atrial Natriuretic factor (ANF), a
marker of cardiomyocyte stretch, was also increased (+87%,
p,0.05) in CT but not in DN-EGFR mice (Fig. 1b). These data
confirm that EGFR activation is required for AngII induced
cardiac remodelling.
DN-EGFR mice and NAS treatment
The nephrectomy/aldosterone/salt treatment (thereafter called
NAS) induces hypertension and cardiovascular remodelling [11]
and was used to evaluate the response of mice with defective
EGFR signalling to chronic aldosterone challenge. Two weeks of
NAS led to renal hypertrophy (Table 2) but did not alter HW/TL
ratio of both CT and DN-EGFR mice (Fig. 1c). The left ventricle
(LV) end-diastolic diameter/ body weight ratio estimated by
echocardiography indicated the absence of LV dilation (Table 3).
Echocardiographic assessment of systolic function with several
parameters including ejection fraction and tissue Doppler imaging
revealed no systolic dysfunction in NAS treated animals. In
contrast, we detected a mild alteration of diastolic function in NAS
groups as indicated by the increased isovolumic relaxation time
(IVRT) but no significant alteration of tissue Doppler parameters
(Ea, Epw) (Table 3). Although cardiac hypertrophy was still not
Table 1. Primers sequences.
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treatment in both CT and DN-EGFR mice (Fig. 1d).
These data suggest that when EGFR activation is defective in
cardiomyocytes, it does not affect cardiac remodelling in response
to aldosterone challenge. However, although the duration of our
treatment was similar to that of AngII treatment, it was too short
to induce cardiac hypertrophy in CT mice. We thus extended
treatment duration (two more weeks) to induce cardiac hypertro-
phy in CT mice and get a more robust conclusion about the role of
EGFR in cardiac effects of aldosterone.
Under basal conditions, blood pressure was similar between CT
and DN-EGFR mice and similarly affected by NAS: systolic blood
pressure increased with the same amplitude in both genotype (CT:
+21%, DN-EGFR: +24%, p,0.05 vs respective sham) (Table 2).
Renal hypertrophy was also induced to a similar extent in CT and
DN-EGFR mice (Table 2).
As expected, one month of NAS led to cardiac hypertrophy in
CT mice (Fig. 2a) but also in DN-EGFR mice (CT: +17%, DN-
EGFR: +16%, p,0.05 vs respective sham). Mineralocorticoid
receptor expression (mRNA) was not altered (data not shown).
Echocardiographic parameters were similar to those obtained by
the shorter treatment: NAS treatment altered midly diastolic but
no systolic function in both CT and DN-EGFR mice (Table 4). As
for shorter treatment, NAS similarly increased cardiac ANF, BNF
and b-MHC expression in CT and DN-EGFR mice (Fig 2.b–c).
The cardiac expression of collagen 1A and 3A isoforms known to
be increased by NAS was similar at basal state between CT and
DN-EGFR mice and similarly increased in both groups after one
month of NAS (Fig. 2d), whereas the expression of matrix
metallopeptidase 9 (Mmp9) a matrix degrading enzyme was
decreased by NAS treatment, similarly between control and DN-
EGFR mice (Fig. 2e). A discrete, but not significant, increase in
cardiac fibrosis was observed in both groups after one month NAS
(Fig. 2f). All together, these data indicate that when EGFR
activation is defective in cardiomyocytes, it does not affect the
cardiac molecular remodelling in response to aldosterone
challenge, while it does in response to AngII. Taken together
these observations do not support the hypothesis that cardiac
EGFR signalling plays a role in aldosterone-induced cardiac
pathology.
Figure 1. Cardiac phenotype of CT and DN-EGFR mice after two weeks of Angiotensin II or aldosterone (NAS) treatment. A: Heart
weight to tibia length ratio of CT and DN-EGFR mice under basal conditions or after two weeks of Angiotensin II infusion. Values are means 6 SEM,
n=3–6 mice per group. *p,0.05, Angiotensin II-treated mice versus corresponding Sham. B: Cardiac ANF mRNA expression of CT and DN-EGFR mice
under basal conditions or after two weeks of Angiotensin II infusion. Values are expressed relative to those for UBC 6 SEM, n=3–6 mice per
condition. *p,0.05, Angiotensin II versus corresponding Sham. C: Heart weight to tibia length ratio of CT and DN-EGFR mice under basal conditions
or after two weeks of Nephrectomy-Aldo-Salt treatment (NAS). Values are means 6 SEM, n=5–6 mice per group. *p,0.05, NAS-treated mice versus
corresponding Sham. D: Cardiac ANF mRNA expression of CT and DN-EGFR mice under basal conditions or after two weeks of NAS treatment. Values
are expressed relative to those for UBC 6 SEM, n=5–6 mice per condition. *p,0.05, NAS versus corresponding Sham.
doi:10.1371/journal.pone.0030156.g001
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The molecular and cellular mechanisms underlying the
deleterious effects of aldosterone in heart are not fully understood.
Interactions between aldosterone and the activation of the
Epidermal Growth Factor Receptor (EGFR) is an attractive
hypothesis which was essentially based on experiments performed
on cultured cells [6]. However, this relation appeared recently to
play an important role in vivo in the functional effects of
aldosterone on vasculature [8]. The aim of our study was therefore
to evaluate this possible interaction in the heart in vivo, using a
transgenic model of EGFR-deficient activation.
Analysing the role of EGFR in vivo is not easy since this receptor
is involved in many cellular processes. Total EGFR inactivation
using global targeted gene inactivation leads to developmental
abnormalities or lethality depending of the genetic background of
the animal [12], and its chronic pharmacologic inhibition using
tyrosine kinases inhibitors induces serious side effects such as
diarrhoea, weight loss and death (personal data and [13]). To
avoid these effects, we used a mouse model with cardiomyocyte-
targeted expression of a dominant-negative EGFR (DN-EGFR).
Furthermore, the use of this model allowed discriminating between
EGFR inactivation effects restricted to cardiomyocytes or in all
cardiac cell types.
EGFR specific tyrosine kinases inhibitors like gefitinib and
erlotinib received regulatory approval for use in cancer patients
[14]. However although the long-term physiological consequences
of suppressed EGFR activity are unknown, cardiac toxicity is
already a concern [15]. We previously reported that EGFR
deficiency in all cardiac cell types (waved-2 mice) led to mild
cardiac hypertrophy [8] whereas the cardiomyocyte-specific
decrease in EGFR activity (DN-EGFR mice) did not. This
suggests that non-cardiomyocyte cells could be at the origin of
cardiac side effects related to EGFR inhibition in human
therapeutics.
Recent in vivo and in vitro studies provide strong evidence of an
interaction between MR and the EGFR signalling pathways,
showing both induction of transactivation and expression of the
Table 2. General characteristics of CT and DN-EGFR mice
after 2 or 4 weeks of aldosterone (NAS) treatment.





2 weeks of treatment
n 655 4
BW (g) 2561.4 2561.1 2660.4 2560.7
TL (mm) 16.360.1 16.460.2 16.560.2 16.560.1
KW/TL (mg/mm) 14.260.8 13.760.3 16.960.5* 16.860.8*
4 weeks of treatment
n 545 4
BW (g) 3360.3 3460.2 34613 2 61
TL (mm) 17.360.4 17.160.2 17.060.3 16.860.4
KW/TL (mg/mm) 21.760.7 21.960.3 29.961.5* 27.961.9*
SBP (mmHg) 11162 11262 13463* 13964*
BW: body weight; TL: tibia length; KW: kidney weight; SBP: Systolic Blood
Pressure.
*p,0.05 vs corresponding Sham.
doi:10.1371/journal.pone.0030156.t002
Table 3. Echocardiographic data of DN-EGFR or CT mice after 2 weeks of aldosterone treatment (NAS).
CT sham CT NAS DN-EGFR sham DN-EGFR NAS
n6 5 5 5
Body Weight (g) 2460.8 24.160.5 23.860.9 2460.6
Age (day) 68646 7 636 5 627 1 63
Heart rate (bpm) 506612 474695 3 7 615 470625
Cardiac and vascular remodelling
Diastolic Ao (mm) 1.3660.04 1.2560.05 1.360.08 1.3260.05
LA (mm) 2.4760.05 2.5160.12 2.3760.1 2.760.11
LV EDD/BW (mm/g) 0.1660.01 0.1560.005 0.1660.01 0.1560.003
LV mass/BW (mg/g) 4.1460.35 4.4960.2 5.060.23 4.1760.20
LV Systolic function
EF (%) 90628 7 638 3 638 5 62
Vcfc (circ/s) 3.4660.17 2.9960.19 2.960.25 2.6660.11
Sa (cm/s) 2.5260.28 2.7460.08 2.5160.09 2.3460.16
Spw (cm/s) 3.0660.16 2.4860.12 3.0860.17 2.4160.14*
LV Diastolic function
IVRT (ms) 1660.56 20.461.54* 1761.2 1961.04*
Ea (cm/s) 4.660.45 4.5960.21 4.6360.12 4.0460.23
Epw (cm/s) 4.2760.25 4.7860.27 5.160.29 4.4460.32
E/Ea 22.861.52 21.860.64 22.161.25 26.562.2
LA: left atrium; LV EDD: left ventricle end diastolic diameter; BW: body weight; EF: ejection fraction; Vcfc: velocity shortening of circumferential fibers; Sa, Spw: maximal
systolic velocity of the mitral annulus and posterior wall; IVRT: isovolumic relaxation time; Ea and Epw: maximal diastolic velocity of the mitral annulus and the posterior
wall; E: maximal velocity of the LV inflow.
*p,0.05 versus CT-Sham.
doi:10.1371/journal.pone.0030156.t003
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logical experiments showing that different inhibitors of the EGFR
tyrosine kinase abolish aldosterone-induced ERK1/2 phosphory-
lation, and also further downstream events like sodium proton
exchanger activation, DNA synthesis or ACE gene expression in
MDCK cells, CHO cells, HEK cells, VSMC, and endothelial cells
[16] [17] [18] [19] [20] [21]. In addition to aldosterone-induced
EGFR transactivation in cell culture, a MR-dependent increase of
EGFR mRNA or protein has been reported. In vitro, aldosterone
enhanced EGFR expression in cultured kidney and human
vascular smooth muscle cells [22–23]; and in vivo EGFR expression
is enhanced by aldosterone in the aorta, heart and kidney but not
in liver or adipose tissue of adrenalectomized rats. These data
suggested an important functional interaction between aldosterone
and EGFR-mediated pathways. In this study, we report that
EGFR is not required for aldosterone/salt-induced cardiac
hypertrophy and molecular remodelling. In the same way, we
previously reported that EGFR did not affect the vascular
hypertrophy and molecular remodelling induced by aldosterone/
salt although it mediates the vascular dysfunction induced in this
model [8]. Therefore the remodelling effects of aldosterone do not
require EGFR. To date, the interactions between aldosterone/salt
and EGFR in vivo seem thus restricted to vascular functional
effects. Most studies were conducted with vascular cells (endothe-
lial and smooth muscle) [19] [20] [21]; further studies using
cardiomyocytes could help to decipher the interactions between
EGFR and MR at the cardiac level.
Cardiac fibrosis is a hallmark of the NAS model. After one
month NAS, we did not find a significant increase of fibrosis,
despite a trend. Indeed, cardiac fibrosis is a dynamic process,
which requires time to develop. Other studies report no increase in
cardiac fibrosis following 4 weeks of NAS treatment [24] [25].
However, the altered expression of genes of extracellular matrix
composition and homeostasis (increased expression of collagens
and decreased expression of Mmp9) suggests that the process of
cardiac remodelling was initiated, but not affected by the altered
EGFR signalling.
We recently reported evidence that interactions between
systemic AngII and cardiac MR-mediated pathways lead to
increased fibrosis and cardiac remodelling [10], possibly as a
consequence of a cumulative action on oxidative stress in the
absence of inflammation. Combined increases of systemic AngII
and cardiac MR signalling were associated with LV hypertrophy
and diastolic dysfunction, and this was prevented by pharmaco-
logical MR antagonism [10]. Furthermore, there is increasing
evidence that AngII, acting via AT1R, may mediate or even
exacerbate the damaging effects of aldosterone as evidenced by the
beneficial effects of pharmacological AT1R blockade on aldoste-
rone induced remodelling [26,27]. Aldosterone mediated dam-
ages, at least in part, seem thus related to AT1R activated
pathways. However, our results suggest that AngII and NAS
induce cardiac hypertrophy via distinct pathways. Indeed, EGFR
transactivation is a key process in the AngII-mediated cardiac
remodelling as AngII is unable to induce cardiac hypertrophy
Figure 2. Cardiac phenotype of CT and DN-EGFR mice after 4 weeks of aldosterone (NAS) treatment. A- Heart weight to tibia length
ratio of CT and DN-EGFR mice under basal conditions or after 4 weeks of NAS treatment. Values are means 6 SEM, n=3–5 mice per group. *p,0.05,
NAS versus corresponding Sham. B: Cardiac ANF mRNA expression of CT and DN-EGFR mice under basal conditions or after 4 weeks of NAS. Values
are expressed relative to those for UBC 6 SEM, n=3–5 mice per condition. *p,0.05, NAS versus corresponding Sham. C–E: Cardiac BNF and bMHC
(C) , Col1A and Col3A (D) and Mmp9 (E) mRNA expression of CT and DN-EGFR mice under basal conditions or after 4 weeks of NAS. Values are
expressed relative to those for UBC 6 SEM, n=3–5 mice per condition. *p,0.05, NAS versus corresponding Sham. F: Interstitial cardiac fibrosis
quantification. Cardiac fibrosis in CT and DN-EGFR mice under basal conditions or after 4 weeks of NAS. Values are expressed as arbitrary units.
n=3–5 mice per condition.
doi:10.1371/journal.pone.0030156.g002
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NAS induce cardiac hypertrophy even when EGFR activation is
defective in cardiomyocytes. This result is in accord with a
previous study where AT1R blockade has no effect on NAS
induced cardiac hypertrophy [26]. AngII-induced cardiac hyper-
trophy is thus EGFR-dependent whereas that induced by
aldosterone/salt is EGFR-independent.
We demonstrate in the present study that EGFR activation does
not play a significant role in the chronic pathophysiological
consequences of aldosterone in the heart, at least in the NAS
protocol. Our experimental approach does not exclude a role of
EGFR in the rapid, nongenomic effects of aldosterone or a role of
EGFR transactivation by aldosterone in vivo in other cell types, in
particular in smooth muscle cells. Further studies will address this
point.
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